We got a mention...

"Other notable therapies in late-stage development include CytoDyn’s once-weekly leronlimab, which is expected to be used in patients with CCR5-type virus, and Gilead’s biannual injectable lenacapavir for pre-exposure prophylaxis (PrEP)**."

https://www.globaldata.com/media/pharma/hiv-m...lobaldata/